Authorized purpose: Lung-CAD is a computer-assisted detection (CADe) software device that analyzes chest radiograph studies for lung hyperinflation. The device uses a deep learning algorithm to identify regions of interest (ROIs) with lung hyperinflation and produces boxes around the ROIs. Lung-CAD is intended for use as a concurrent reading aid for physicians interpreting chest X-rays. The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Clinical role
Concurrent reading aid that analyzes chest radiographs for lung hyperinflation and draws boxes around detected regions in an overlay the physician can toggle in the PACS viewer; it is not intended for clinical diagnosis of any disease.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Lung-CAD is a computer-assisted detection (CADe) software device that analyzes chest radiograph studies for lung hyperinflation. The device uses a deep learning algorithm to identify regions of interest (ROIs) with lung hyperinflation and produces boxes around the ROIs. Lung-CAD is intended for use as a concurrent reading aid for physicians interpreting chest X-rays. The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Digital X-ray chest radiographs.
Who uses it?Intended users: Physicians interpreting chest X-rays
What does the software produce?Output: For each image within a study, Lung-CAD generates a DICOM Presentation State file (output overlay). If any region of interest (ROI) is detected, the output overlay includes 'Lung hyperinflation' label and bounding boxes surrounding each detected ROI. If no ROI is detected, the output overlay includes the text 'No Lung-CAD ROI(s)' and no bounding boxes are included.
What is its most important limitation?Key limitation: The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Clinical takeaway. Clinical role: Lung-CAD is a computer-assisted detection (CADe) software device that analyzes chest radiograph studies for lung hyperinflation. The device uses a deep learning algorithm to identify regions of interest (ROIs) with lung hyperinflation and produces boxes around the ROIs. Lung-CAD is intended for use as a concurrent reading aid for physicians interpreting chest X-rays. The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Evidence takeaway. Evidence from the reviewed source record: Imagen conducted a standalone performance assessment on 5,000 chest radiograph cases representative of the intended use population. The results demonstrated sensitivity of 0.898, specificity of 0.894, and Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve of 0.964. A fully-crossed multiple reader, multiple case retrospective reader study evaluated 244 cases.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Lung-CAD is a computer-assisted detection (CADe) software device that analyzes chest radiograph studies for lung hyperinflation. The device uses a deep learning algorithm to identify regions of interest (ROIs) with lung hyperinflation and produces boxes around the ROIs. Lung-CAD is intended for use as a concurrent reading aid for physicians interpreting chest X-rays. The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Concurrent reading aid that analyzes chest radiographs for lung hyperinflation and draws boxes around detected regions in an overlay the physician can toggle in the PACS viewer; it is not intended for clinical diagnosis of any disease.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Lung-CAD is a computer-assisted detection (CADe) software device that analyzes chest radiograph studies for lung hyperinflation. The device uses a deep learning algorithm to identify regions of interest (ROIs) with lung hyperinflation and produces boxes around the ROIs." … "Lung-CAD is intended for use as a concurrent reading aid for physicians interpreting chest X-rays. The device is not intended for clinical diagnosis of any disease.". Read from the exact FDA decision document on 2026-11-14.
The exact subject-device table identifies the image source as Digital X-ray and the study type as Chest; the current generic data and consult-instruction wording is not retained.
For each image within a study, Lung-CAD generates a DICOM Presentation State file (output overlay). If any region of interest (ROI) is detected, the output overlay includes 'Lung hyperinflation' label and bounding boxes surrounding each detected ROI. If no ROI is detected, the output overlay includes the text 'No Lung-CAD ROI(s)' and no bounding boxes are included.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
The device is not intended for clinical diagnosis of any disease. It does not replace the role of the physician or of other diagnostic testing in the standard of care for lung parenchymal findings. Lung-CAD is indicated for adults only.
Exact FDA submission
Checked 2026-09-19
The exact indications state the diagnostic, physician, testing, and adult-population boundaries; they do not state the current scanner-manufacturer or exclusion-criteria wording.
Imagen conducted a standalone performance assessment on 5,000 chest radiograph cases representative of the intended use population. The results demonstrated sensitivity of 0.898, specificity of 0.894, and Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve of 0.964. A fully-crossed multiple reader, multiple case retrospective reader study evaluated 244 cases.
Exact FDA submission
Checked 2026-09-19
The exact packet reports sensitivity, specificity, and ROC AUC, not the current rounded accuracy label, and separately reports the 244-case reader study.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Imagen conducted a standalone performance assessment on 5,000 chest radiograph cases representative of the intended use population. The results demonstrated sensitivity of 0.898, specificity of 0.894, and Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) curve of 0.964. A fully-crossed multiple reader, multiple case retrospective reader study evaluated 244 cases.
FDA source
Exact FDA submission
Checked 2026-09-19
The exact packet reports sensitivity, specificity, and ROC AUC, not the current rounded accuracy label, and separately reports the 244-case reader study.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Lung-CAD regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K230085
Samplen=5000
IndependenceIndependence not established
K230085
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K230085. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Digital X-ray chest radiographs.
Scope: Exact FDA submission. The exact subject-device table identifies the image source as Digital X-ray and the study type as Chest; the current generic data and consult-instruction wording is not retained.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: For each image within a study, Lung-CAD generates a DICOM Presentation State file (output overlay). If any region of interest (ROI) is detected, the output overlay includes 'Lung hyperinflation' label and bounding boxes surrounding each detected ROI. If no ROI is detected, the output overlay includes the text 'No Lung-CAD ROI(s)' and no bounding boxes are included.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: For each image within a study, Lung-CAD generates a DICOM Presentation State file (output overlay). If any region of interest (ROI) is detected, the output overlay includes 'Lung hyperinflation' label and bounding boxes surrounding each detected ROI. If no ROI is detected, the output overlay includes the text 'No Lung-CAD ROI(s)' and no bounding boxes are included.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Imagen's security policy (effective 2024-04-02) states HIPAA, HITRUST CSF and SOC 2 Type II compliance, encryption in transit and at rest, least-privilege access, multi-factor authentication, audit trails and incident response. Vendor statement; no report or certificate was read.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: the policy is on imagen.ai, whose AI software page lists this product by name, and the FDA letter for this entry names Imagen Technologies, Inc. (New York). The policy is company-wide; exact-release scope is not established. A 2023 HITRUST release names the Care Delivery Services platform, not the devices, and is not applied.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
26Fields reviewed
10Source classes checked
14Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 14 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 14 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K230085 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Lung-CAD is a concurrent-read computer-aided detection aid for identifying and marking regions of interstitial thickening on adult chest radiographs; it does not provide a clinical diagnosis or replace physician review or other tests.
Authorized purpose: Provides computer-aided triage, notification, and diagnostic assistance for detecting and localizing pneumothorax on frontal chest X-rays.
Authorized purpose: Second-reader support for radiologists reviewing adult digital AP or PA chest radiographs, with suspected pulmonary nodules in the 6-30 mm range marked for review.
Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.